Tempest Therapeutics, Inc.
TPST · XNASCIK 1544227fmd_05185THPF8BZE026HQSDHH63KXManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2011 to Jun 30, 2026, 61 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 0 | – | – | – | – | – | – | – | – |
| Cost of revenue | 5 | 1 | – | – | – | – | – | – | – | – |
| Gross profit | (5) | (0) | – | – | – | – | – | – | – | – |
| Research and development | 22 | 15 | 14 | 28 | 14 | 17 | 23 | 17 | 28 | 13 |
| Selling, general and administrative | 49 | 28 | – | – | – | – | – | – | – | – |
| Total operating expenses | 82 | 51 | – | – | – | – | – | – | – | – |
| Operating income | (81) | (84) | (27) | (45) | (19) | (27) | (35) | (29) | (42) | (27) |
| Interest expense | – | 0 | 0 | – | 0 | 1 | 2 | 1 | 1 | 0 |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (0) | (0) | – | – | 0 | (1) | (1) | (0) | 0 | 0 |
| Income before taxes | (82) | (51) | – | – | – | – | – | – | – | – |
| Income tax expense | 0 | 0 | – | – | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (82) | (51) | – | – | – | – | – | – | – | – |
| Net income | (82) | (85) | (27) | (45) | (19) | (28) | (36) | (29) | (42) | (26) |
| Net income to common shareholders | (82) | (51) | – | – | – | – | – | – | – | – |